Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Assets Average (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Assets Average for 10 consecutive years, with $189.3 million as the latest value for Q4 2025.

  • Quarterly Assets Average changed N/A to $189.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $48.6 million for FY2023, 33.55% down from the prior year.
  • Assets Average for Q4 2025 was $189.3 million at Crescent Biopharma, up from $147.9 million in the prior quarter.
  • The five-year high for Assets Average was $189.3 million in Q4 2025, with the low at $10.8 million in Q1 2025.
  • Average Assets Average over 5 years is $79.8 million, with a median of $65.4 million recorded in 2023.
  • Peak annual rise in Assets Average hit 637.1% in 2025, while the deepest fall reached 72.72% in 2025.
  • Over 5 years, Assets Average stood at $101.1 million in 2021, then tumbled by 46.72% to $53.9 million in 2022, then fell by 8.59% to $49.3 million in 2023, then plummeted by 59.28% to $20.1 million in 2024, then soared by 843.65% to $189.3 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $189.3 million, $147.9 million, and $81.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.